Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561570 | 1.00 | CTSK (0.55) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL506750 | 1.00 | CTSK (0.55) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL20542796 | 0.89 | CTSK (0.70) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL20542797 | 0.89 | CTSK (0.70) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL12155120 | 0.88 | CTSK (0.56) | CTSKCTSSCAPN1CTSLCTSB | |
| SCHEMBL24072863 | 0.88 | CTSK (0.54) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL13501917 | 0.87 | CTSK (0.46) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL20543144 | 0.86 | CAPN1 (0.72) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL20542827 | 0.86 | CAPN1 (0.72) | CTSKCTSSCAPN1TDP1PTPN1 | |
| SCHEMBL23007632 | 0.86 | CTSK (0.53) | CTSKCTSSCAPN1TDP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853452-B2 | Compounds, their syntheses, compositions, and methods to treat cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010093615-A2 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | TULANE UNIVERSITY (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | SGMS1, PHOSPHO1, MCL1 | CTSK 337/4885CTSS 223/4885CAPN1 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.